Hernández ÁC, Romo AC, Clemenceau JR, Valenzuela TJ, Ayala PBF

Language: Spanish
References: 12
Page: 189-193
PDF size: 173.49 Kb.

ABSTRACT

Introduction: Breast cancer is the leading cause of death in women in Mexico, and this is a heterogeneous disease, which requires a multidisciplinary approach, with the appropriate technological support to implement therapeutic strategies based on their classification and degree of malignancy which could inference of the prognosis and treatment, as well as in the patients with advanced disease could promote the quality of life and survival. Objective: Determine the characteristics, surgical, histopathology and immunohistochemical of patients with a diagnosis of Breast Cancer at the Hospital Ángeles Pedregal. Material and methods: We realize a retrospective, descriptive, longitudinal study, where 417 clinical records and histopathological reports were analyzed during the period from January 2009 to December 2013. Results: We obtained from the 417 cases that the main histopathological type was the ductal infiltrating carcinoma with 71.94%. Surgical conservative treatment was conducted in a 25% while radical treatment was made in 37%. The Mortality rate was 1.9% which results below the national average. Conclusions: It is essential to recognize that the morbidity of this pathology is duly detectable and close monitoring is essential to improve the quality of life of the patients.

REFERENCES

1. McDonald S, Saslow D, Alciati MH. Performance and reporting of clinical breast examination: a review of the literature. CA Cancer J Clin. 2004; 54 (6): 345-361.

2. Mahoney L, Csima A. Efficiency of palpation in clinical detection of breast cancer. Can Med Assoc J. 1982; 127 (8): 729-730.

3. Agarwal T, Patel B, Rajan P, Cunningham DA, Darzi A, Hadjiminas DJ. Core biopsy versus FNAC for palpable breast cancers. Is image guidance necessary? Eur J Cancer. 2003; 39 (1): 52-56.

4. Pérez-Sánchez VM, Vela-Chávez TA, Mora-Tiscareño A. Diagnóstico histopatológico y factores pronósticos en cáncer infiltrante de la glándula mamaria. Cancerología. 2008; 3: 7-17.

5. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98 (19): 10869-10874.

6. Slodkowska EA, Ross JS. MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn. 2009; 9 (5): 417-422.

7. Albain KS, Paik S, van’t Veer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast. 2009; 18 Suppl 3: S141-S145.

8. Huicochea-Castellanos S, González-Balboa P, Tovar-Calderón IL, Olarte-Casas MA, Vázquez-Lamadrid J. Cáncer de mama. Anales de Radiología México. 2009; 8 (1): 117-126.

9. Ziv E. Genética del cáncer de mama: aplicaciones para la población mexicana. Salud Pública Mex. 2011; 53 (5): 415-419.

10. Mohammed RH, Lakatua DJ, Haus E, Yasmineh WJ. Estrogen and progesterone receptors in human breast cancer. Correlation with histologic subtype and degree of differentiation. Cancer. 1986; 58 (5): 1076-1081.

11. Salinas-Martínez AM, Juárez-Ruiz A, Mathiew-Quirós A, Guzmán-De la Garza FJ, Santos-Lartigue A, Escobar-Moreno C. Cáncer de mama en México: tendencia en los últimos 10 años de la incidencia y edad al diagnóstico. Rev Invest Clin. 2014; 66 (3): 210-217.

12. Mohar A, Reynoso N, Villarreal-Garza C, Bargalló-Rocha JE, Arce-Salinas C, Lara-Medina F. Cáncer de mama en el Instituto Nacional de Cancerología. Experiencia del Seguro Popular 2007-2013. Rev Mex Mastol. 2015; 5 (1): 6-11.